Table 2.

Model 1 Linear regression results between a blood biomarker and an imaging biomarker

	Serum NfL			Plasma NTA			Plasma t-tau			Plasma GFAP
Predictors	Estimate	R2	p	Estimate	R2	p	Estimate	R2	p	Estimate	R2	p
WMH, slope (95% CI)	0.011 (0.0044 to 0.019)	0.18	0.017	0.0047(-0.012 to 0.022)	0.072	0.62	-0.004 (-0.012 to 0.0036)	0.075	0.37	0.0064 (-0.0023 to 0.015)	0.0066	0.20
MTA, slope (95% CI)	0.16 (0.038 to 0.28)	0.14	0.025	0.42 (0.13 to 0.71)	0.19	0.026	0.063 (-0.045 to 0.21)	0.082	0.29	0.20 (0.067 to 0.34)	0.11	0.022
PiB, slope (95% CI)	0.15 (-0.029 to 0.32)	0.030	0.15	0.16 (-0.26 to 0.58)	-0.0080	0.53	0.074 (-0.12 to 0.27)	-0.0075	0.52	0.26 (0.069 to 0.46)	0.10	0.022

Serum NfL = neurofilament light, Plasma NTA = N-terminal tau marker, Plasma t-tau = Quanterix total tau marker, Plasma GFAP = glial fibrillary acidic protein, WMH = volumes of white matter hyperintensities, MTA = medial temporal lobe atrophy score, PiB = [¹¹C]PiB composite score. Blood biomarker values are log transformed. WMH and MTA adjusted for MRI scanner. P < 0.05 are bolded. P-values are FDR-corrected including all p-values from tables 1, 2, 3, and 4. Blood biomarker values were log transformed